Literature DB >> 3370821

GC and GC-MS procedures for simultaneous phenotyping with dextromethorphan and mephenytoin.

P Baumann1, M Jonzier-Perey.   

Abstract

A genetic deficiency in the metabolism of dextromethorphan and mephenytoin may be revealed by the excretion pattern of dextromethorphan and its metabolite dextrorphan, and mephenytoin, 4-OH-mephenytoin, respectively, after a single dose of the test drugs. Existing methods were modified for determining the compounds in 0.1-0.5 ml urine samples. No prior derivatization of the compounds was necessary before their gaschromatographic or mass-spectrometric analysis by using crosslinked 5% phenylmethyl silicone fused silica columns. Seven healthy volunteers were phenotyped at weekly intervals with either 25 mg dextromethorphan or 100 mg mephenytoin, or both drugs. One subject was a poor metabolizer of mephenytoin, while all subjects were extensive metabolizers of dextromethorphan. Neither a pharmacokinetic nor an analytical interference was observed when the results of the single test were compared with those of the combined test. The results of the mephenytoin test were also tentatively given in form of metabolic ratios. The GC-MS assay was designed for clinical studies so that patients treated with other drugs could be phenotyped.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3370821     DOI: 10.1016/0009-8981(88)90146-5

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  6 in total

1.  Clinical implications of slow sulphoxidation of thioridazine in a poor metabolizer of the debrisoquine type.

Authors:  J W Meyer; B Woggon; P Baumann; U A Meyer
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Omission of the deconjugation step in urine analysis and the unaltered outcome of CYP2D6 phenotyping with dextromethorphan.

Authors:  N E Basci; A Bozkurt; S O Kayaalp; A Sayal; A Isimer
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Jan-Mar       Impact factor: 2.441

3.  Metabolic disposition of ajmaline.

Authors:  C Köppel; J Tenczer; I Arndt
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1989 Oct-Dec       Impact factor: 2.441

4.  Drug refractory epilepsy in brain damage: effect of dextromethorphan on EEG in four patients.

Authors:  B Schmitt; R Netzer; S Fanconi; P Baumann; E Boltshauser
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-03       Impact factor: 10.154

5.  Rapid screening for polymorphisms in dextromethorphan and mephenytoin metabolism.

Authors:  R J Guttendorf; M Britto; R A Blouin; T S Foster; W John; K A Pittman; P J Wedlund
Journal:  Br J Clin Pharmacol       Date:  1990-04       Impact factor: 4.335

Review 6.  New insights into natural products that target the gut microbiota: Effects on the prevention and treatment of colorectal cancer.

Authors:  Lu Lu; Jiahuan Dong; Yujing Liu; Yufan Qian; Guangtao Zhang; Wenjun Zhou; Aiguang Zhao; Guang Ji; Hanchen Xu
Journal:  Front Pharmacol       Date:  2022-08-15       Impact factor: 5.988

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.